Areas of Focus
Aspiring to Introduce
a Paradigm Shift
for Cardiac Therapy
We are a Phase 3, clinical-stage biopharmaceutical company dedicated to developing etripamil for the treatment of episodic cardiovascular indications.
A common and recurring arrhythmia starting and stopping without warning
A common arrhythmia with an irregular and rapid heart rate
Conditions that may benefit from the unique profile of etripamil
PSVT is a common and recurring rapid heartbeat caused by abnormal electrical signals. Symptoms may include palpitations, sweating, chest pressure or pain, shortness of breath, sudden onset of fatigue, lightheadedness or dizziness, fainting or anxiety.
Atrial fibrillation is a common arrhythmia with an irregular, and often rapid, heartbeat caused by abnormal electrical signals in the upper chambers of the heart that may increase the risk of stroke, heart failure, and other heart-related complications.
Angina is chest discomfort caused by an imbalance between the supply of oxygen to and the demand for oxygen by the heart. It is primarily, but not always, caused by either a blockage or spasm of the coronary arteries.
PSVT is a common condition consisting of a recurring and rapid heartbeat caused by abnormal electrical “wiring” in the heart. Symptoms may include palpitations, sweating, chest pressure or pain, shortness of breath, sudden onset of fatigue, lightheadedness or dizziness, fainting, or anxiety.
AFib with RVR is an abnormal heart beat occurring in the top heart chambers that is often symptomatic and frequently requires treatment in an acute care setting.
Based on its novel pharmacology, etripamil may have other cardiac and potentially non-cardiac uses beyond the treatment of PSVT and AFib derived from its AV nodal-blocking and/or vasodilatory effects similar to other calcium channel blockers.